In a nude mouse model of hepatocellular carcinomas, a therapy with a neutralizing antibody against serum levels of progranulin led to inhibition of tumor growth in a dose-dependent manner and reduced angiogenesis in vitro and in vivo [39]. Here, GRN is linked to hepatocellular carcinoma.